扶正解毒化瘀法治疗老年肺炎的理论探讨与临床评价研究
|
摘要
目的
肺炎是老年人最为常见的肺部感染性疾病,一般病情严重,预后险恶。老年肺炎的发病率和病死率显著高于青年人。年龄、基础病、曾因CAP住院、营养不良等是其重要的危险因素。细菌感染是老年人肺炎最主要的病原菌,革兰氏阴性杆菌产生的内毒素,能引起严重的炎症级联反应,促使SIRS的发生,进而发展至MODS,导致老年肺炎患者死亡。这一病理过程与中医“风温肺热病”的核心病机比较一致。“热毒炽盛、痰瘀互结、正气亏虚”是贯穿老年肺炎始终的核心病机。风温毒邪是其主要致病因子,热毒之邢存在于病变的始终,热毒炽盛、气阴耗伤,导致痰瘀互结,胶着难去,是导致风温肺热病预后凶险的关键。我们抓住老年肺炎的核心病机,遵循扶正祛邪治则,确立扶正解毒化瘀治法,以期降低老年肺炎病死率。该论文研究目的主要是：①探讨老年肺炎的核心病机和扶正解毒化瘀治法；②评价扶正解毒化瘀法干预老年肺炎病死率的有效性和安全性；③分析总结老年肺炎的中医病因、发病特点以及中医证候分布规律等,为制定扶正解毒化瘀法治疗老年肺炎的诊疗技术规范提供临床证据。
对象与方法
论文的主要研究对象为≥65岁的老年人肺炎住院患者。老年肺炎归属于中医“风温肺热病”范畴,中医文献是中医理论知识与临床经验的载体,是中医学术研究和临床应用的基础,在文献学习粤临床实践的基础上对老年肺炎的中医病机和治法进行理论探讨。
本研究为多中心随机双盲安慰剂对照试验。在5个分中心开展,将308例老年肺炎患者随机分为治疗组和对照组,两组各154例。治疗组采用西医基础抗感染治疗加扶正解毒化瘀颗粒治疗,对照组采用西医基础抗感染治疗加安慰剂治疗。
本研究疗程为1月,死亡和治愈(或好转)出院为终点事件,用药时间不超过4周。分别于治疗后第7天评测症状积分、胸片、血常规、血气分析、体温；第14天评测症状积分、血常规、痰涂片、细菌培养、咽拭子找支原体、血气分析、体温；第21天评测症状积分、胸片、血常规、血气分析、体温；第28天评测症状积分、胸片、血常规、痰涂片、细菌培养、咽拭子找支原体、血气分析、生命体征、尿便常规、肝肾功、心电图。死亡事件粤不良事件随时记录。
本论文主要统计分析基线资料；肺炎30天病死率；治疗后1周、2周的治愈率、症状积分、胸片吸收程度、血常规、血气分析及体温的变化情况。安全性评价采用报告表记录患者不良事件,并对治疗前后尿、大便常规,肝肾功能,心电图进行评价。
结果
通过文献学习、前期工作及临床实践总结,我们认为风温毒邪是老年性肺炎主要致病因素；热毒炽盛、痰瘀互结、正气亏虚是其核心病机。针对核心病机,治以扶正解毒化瘀法,中西医结合治疗可以提高疗效,具有降低病死率的趋势。临床试验共入组303例受试者。脱落17例,剔除2例,最后共有284例纳入统计分析。临床试验结果表明：
1治疗组发生死亡20例(13.89%),与对照组死亡16例(11.43%)比较,无统计学意义(p>0.05),这与样本量较少可能有关。但治疗组总病死率低于文献报道的30%-50%这一平均病死率,仍具有降低病死率的临床趋势,进一步扩大样本量可能出现统计学差异。
2两组第1周治愈率四分类等级分析,无统计学意义,但治疗组的趋势仍较对照组明显治疗组第2周有效率明显优于对照组,经X2检验,两组间有显著性差异(p=0.042)。结果表明,西医抗感染基础上配合中医扶正解毒化瘀法治疗老年肺炎,在一定程度上可以提高其临床疗效。
3治疗组在治疗后第1周、第2周能够明显改善咯痰症状积分,与对照组比较有统计学意义(p>0.05)；其它症状(咳嗽、发热、胸闷痛、气短懒言、喘息、口干舌燥、大便干结等)治疗前后有明显差异,但组间比较则无显著差异(P>0.05)。扶正解毒化瘀法能够在第1周改善咳痰症状；在第2周能够明显改善喘息、气短懒言等症状；但咳嗽、胸闷痛、倦怠乏力、口干舌燥、大便干结等症状治疗后的起效时间不确定。
4两组治疗后第1周、第2周外周血白细胞总数与中性粒细胞百分比均逐渐下降,治疗组下降趋势较对照组明显,但治疗组与对照组之间比较无显著差异(P>0.05)。扶正解毒化瘀法降低白细胞和中性粒细胞方面可能有一定优势,但是未发现统计学差异。
5随着治疗时间延长,两组血氧分压逐渐上升,二氧化碳分压逐渐下降；治疗组在治疗后第1周二氧化碳分压下降较对照组差异有统计学意义(P=0.039)；但两组间血氧分压升高比较则无显著差异(P>0.05)。
6本组资料中共有57例患者入组前有发热,对其服药后4h体温进行K-S检验,则4组数据都服从正态分布(P>0.05)。对两组间4个时间点作组间差异的t检验,则每个时间点上均无显著差异(P>0.05)。但从体温变化曲线来看,治疗组体温下降幅度略大于对照组,可以看出扶正解毒化瘀法具有即时退热的趋势。
7本组老年肺炎患者影像学资料具有以下特点：①病变部位多在下肺野；②病灶形态多数表现为肺纹理增重、模糊、紊乱,网格状阴影,斑点状或斑片状阴影,一般病变范围比较广泛；③支气管肺炎者居多；④容易伴发胸腔积液、肺气肿、肺不张等。两组治疗后胸片显示均存在一定程度的吸收或进展,但治疗后两组间比较并无显著性差异(P>0.05)。老年肺炎患者的炎症消散粤吸收一般需要2～3月时间,本研究资料集中在10～14天,故没能明确反映出两组间的差异。
8扶正解毒化瘀法安全性较好,治疗组144例患者中2例发生不良反应,发生率为1.39%；对照组140例患者中有3发生不良反应,发生率为2.14%；组间比较差别无统计学意义(P>0.05)。两组均未发生导致病例脱落的不良事件和严重不良事件。
结论
1老年肺炎的核心病机是热毒炽盛、痰瘀互结、正气亏虚,扶正解毒化瘀法是治疗老年肺炎的有效治法;
2扶正解毒化瘀法可以在第2周明显提高老年肺炎的治愈率；能够改善咳痰等单项症状积分,对咳痰、气短懒言、喘息等起效时间较早,显示该治法可以有效改善老年肺炎主要临床症状
3扶正解毒化瘀法能够改善老年肺炎的部分实验室指标,对降低外周血白细胞总数、中性粒细胞百分比等,具有一定的趋势；能够提高动脉血氧分压、降低二氧化碳分压,对于改善通气功能具有一定作用；
4扶正解毒化瘀法治疗老年肺炎,是通过干预老年肺炎病变过程中的“热、毒、痰、瘀、虚”等病理变化起作用；
5针对核心病机,确定扶正解毒化瘀法治疗老年肺炎,可以提高老年肺炎的治疗效果,在一定程度上反映出了老年肺炎发生、发展的内在规律；
6扶正解毒化瘀法治疗老年肺炎,在降低病死率方面有一定趋势,但与对照组比较无显著差异,可能粤样本量小有关,有待扩大样本量进一步研究；
7扶正解毒化瘀法治疗老年肺炎安全性较好,可以推广应用。
Objective
Senile Pneumonia is the most common lung infection in old population, notorious with its serious condition and bad prognosis. Morbidity and mortality of Senile Pneumonia are significantly higher than that of pneumonia in young people. Age, underlying disease, hospitalization caused by CAP and malnutrition are major risk factors of Senile Pneumonia. Bacterial infection is the most important pathogens of Senile Pneumonia.Endotoxin produced by Gram-negative bacteria can cause severe inflamm-ation cascade which promote the occurrence of SIRS, even the development of MODS, leading to death of patients. This pathological process is accordant with that of lung heat disease with wind-warm syndrome. "exuberance of heat-toxicity、intermingled phlegm and blood stasis、deficiency of vital qi "is the core pathogenesis of senile pneumonia. Wind-warm and toxicity pathogen are the main pathogenic factor. Heat and toxicity pathogens are always present in the whole course of the disease. The entanglement of exuberance of heat-toxicity、intermingled phlegm and blood stasis、over consumption of qi and fluid is the key factor leading to the extremely dangerous progress of lung heat disease with wind-warm syndrome. In order to reduce the mortality of senile pneumonia, we grasp the core of the pathogenesis of senile pneumonia, follow the principle of "strengthening vital qi to eliminate pathogenic factor", and establish the treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis". The purpose of our research is:①discuss the core of the pathogenesis of senile pneumonia and the treatment method of "strengthening vital qi,removing blood stasis";②evaluate the efficacy and safety of treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" in the intervention in elderly pneumonia mortality;③analyse causes, clinical features and distribution of syndromes, so as to provide clinical evidence for settlement of technical specifications of treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis".
Methods
The main object of the study are hospitalized pneumonia patients who are more than 65 years old. Senile Pneumonia is attributed to "lung heat disease with wind-warm syndrome"in Chinese medicine. Literatures of Chinese medicine are carrier of Chinese medicine theory and clinical experience and the basis for research and clinical application. Through learning literatures and clinical practice, we study the pathogenesis and treatment method of senile pneumonia in the theoretical layer.
Clinical research is conducted in five centers and the patients are divided into treatment group and control group according to the principles of randomization, with 154 cases of subjects in each group. The treatment group is interfered with anti-infection treatment and FuZhengJieDuHuaYu particle treatment, while the control group is interfered with anti-infection treatment and placebo.
The treatment lasts for one month, death and discharge after cure (or improvement) are the end of the treatment and the time for medication is no longer than 4 weeks.7 days after treatment, symptom score evaluation、chest radiograph、blood routine、blood gas analysis and body temperature are obtained; 14 days after treatment, symptom score evaluation、blood routine、sputum smear, bacterial culture、throat swab to find mycoplasma、blood gas analysis and body temperature, are obtained; 21 days after treatment, evaluation of symptom score, chest radiograph, blood routine, blood gas analysis and body temperature are obtained; 28 days after treatment, evaluation of symptom score, chest radiograph, blood routine, sputum smear, bacterial culture, throat swab to find mycoplasma, blood gas analysis, vital signs, urine and stool routine, liver and kidney function, ECG are obtained. Deaths and adverse events are recorded whenever they occur.
This study foucses on statistical analysis of baseline data; 30-day mortality of pneumonia; the cure rate, symptom score, chest X-ray absorption, blood routine, blood gas analysis and temperature changes 1 week and 2 weeks after treatment respectively. Safety evaluation is conducted by record of adverse reactions in patients, and evaluation of blood, urine and stool routine, liver and kidney function, ECG before and after treatment.
Results
Through literature study, preliminary work and summary of clinical practice, we believe that wind-warm and toxicity pathogen are the major risk factor of senile pneumonia; exuberance of heat-toxicity、intermingled phlegm and blood stasis、deficiency of vital qi are the core pathogenesis. Interfered with "strengthening vital qi,clearing toxicity,removing blood stasis" treatment,which is aimed at the core pathogenesis, therapy combined with westen and Chinese medicine can improve the efficacy of treatment with lower mortality.303 cases of clinical trial subjects were enrolled in this research,17 cases of which are lost and 2 cases are excluded and finally 284 cases are statistically analysed. Clinical trial results show that:
1 20 death cases in the treatment group (13.89%),16 death cases in the control group (11.43%) with no statistically significant difference (p>0.05), which may be related to small sample size. But overall mortality rate of the treatment group is lower than 30% to 50%, which is the average mortality rate reported by literature.If the sample size is enlarged, there may be statistical significance between the two groups.
2 Four classification level analysis of cure rate lweek after treatment shows no significant statistical difference between the two groups; chi-square test shows efficacy of treatment group is higher than that of control group with significant difference (p=0.042). The results show that anti-infection treatment combined with traditional Chinese medicine, to some certain extent, can improve clinical efficacy in the treatment of senile pneumonia.
3 Cough symptom score in treatment group can be obviously improved 1 week and 2 weeks after treatment with statistical significance compared with that of control group (p <0.05); other symptoms (cough, fever, chest pain, shortness of breath, disinclination to talk, breathe, dry mouth, dry stool, etc.) are significantly different before and after treatment, but between the two groups had no significant difference (p>0.05). The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" can relieve sputum in the first week after treatment; Symptoms such as breathing, shortness of breath and disinclination to talk can be significantly improved 2 weeks after treatment; but the time when cough, chest pain, malaise, fatigue, dry mouth, dry stools and other symptoms are effectively improved after treatment is uncertain.
4 WBC and neutrophil percentage have decreased in both groups with no significant difference (P>0.05).There may be some advantages for the treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" to reduce white blood cells and neutrophils, but there is no significant difference between the two groups.
5 As treatment time passes, blood oxygen gradually increases and carbon dioxide partial pressure decreases in both groups; partial pressure of carbon dioxide of treatment group compared with the control group decreased significantly 1 week after treatment (P=0.039); but there was no significant difference of the elevated blood oxygen pressure compared between the groups (P>0.05).
6 57 patients were with fever before they are enrolled, K-S test of their body tempera-ture 4 hours after taking the medicine shows the four sets of data are normally distributed (P> 0.05). Of the four time points between the two groups for differences between groups t-test, each time point were not significantly different (P>0.05). However, changes in body temperature curve show body temperature decrease in treatment group is slightly greater than that in the control group, which indicates real-time effect of decreasing body temperature with the use of the treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis".
7 Imaging data of this group of senile pneumonia has the following characteristics:①lesions are most common in lower lung field;②lesions manifest with blurred, disorder, grid-like shadow, the shadow of spots or patchy, usually the area of lesion is extensive;③bronchial pneumonia is the most common lesion;④usually associated with pleural effusion, emphysema, atelectasis, etc. Chest X-ray shows a degree of absorption and progress of the lesion, but there was no significant difference between the two groups after treatment (P> 0.05). Dissipation and absorption of inflammation in senile pneumonia usually takes 2 to 3 months and this research focuses on 10 to 14 days, thus this study did not clearly reflect the difference between the two groups.
8 The safety of the treatment method of "strengthening vital qi,clearing toxicity, removing blood stasis" is certain, there are only two cases of adverse reactions in 144 cases of treatment group, with an adverse reaction rate of 1.39%; there are three cases of adverse reactions in 140 cases of control group, with an occurance rate of 2.14%; there is no statistically significant difference between the two groups(P>0.05). There are no adverse events or serious adverse events leading to loss of subjects in both groups.
Conclusion
1 Exuberance of heat-toxicity、intermingled phlegm and blood stasis、deficiency of vital qi is the core of the pathogenesis of senile pneumonia and the treatment method of "strengthen-ing vital qi,clearing toxicity,removing blood stasis" is an effective treatment in senile pneumo-ma;
2 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" can significantly improve the cure rate of pneumonia two weeks after treatment; improve sputum and other individual symptom score; and has effect in the early stage to relieve cough, shortness of breath, disinclination to talk and breathing, indicating that the treatment method can effectively improve part of clinical symptoms in senile pneumonia;
3 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" can improve part of the laboratory parameters in senile pneumonia, such as WBC, neutrophils and other inflammatory markers; increase blood oxygen partial pressure, reduce carbon dioxide partial pressure,and improve ventilation to certain extent;
4 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" probably cures senile pneumonia by interfering with key factors in its pathological process, such as heat、toxicity、phlegm、blood stasis, deficiency";
5 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" aimed at the core pathogenesis can improve the treatment effectiveness of pneumonia in the elderly, which to a certain extent, reveals the inherent regularity of pneumonia in the elderly;
6 The fact that there is no significant statistical difference of mortality decrease between two groups may be related to the small sample size, thus sample size needs to be expanded in further study.
7 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" has relatively higher safety in the treatment of senile pneumonia and can be applied extensively.
肺炎是老年人最为常见的肺部感染性疾病,一般病情严重,预后险恶。老年肺炎的发病率和病死率显著高于青年人。年龄、基础病、曾因CAP住院、营养不良等是其重要的危险因素。细菌感染是老年人肺炎最主要的病原菌,革兰氏阴性杆菌产生的内毒素,能引起严重的炎症级联反应,促使SIRS的发生,进而发展至MODS,导致老年肺炎患者死亡。这一病理过程与中医“风温肺热病”的核心病机比较一致。“热毒炽盛、痰瘀互结、正气亏虚”是贯穿老年肺炎始终的核心病机。风温毒邪是其主要致病因子,热毒之邢存在于病变的始终,热毒炽盛、气阴耗伤,导致痰瘀互结,胶着难去,是导致风温肺热病预后凶险的关键。我们抓住老年肺炎的核心病机,遵循扶正祛邪治则,确立扶正解毒化瘀治法,以期降低老年肺炎病死率。该论文研究目的主要是：①探讨老年肺炎的核心病机和扶正解毒化瘀治法；②评价扶正解毒化瘀法干预老年肺炎病死率的有效性和安全性；③分析总结老年肺炎的中医病因、发病特点以及中医证候分布规律等,为制定扶正解毒化瘀法治疗老年肺炎的诊疗技术规范提供临床证据。
对象与方法
论文的主要研究对象为≥65岁的老年人肺炎住院患者。老年肺炎归属于中医“风温肺热病”范畴,中医文献是中医理论知识与临床经验的载体,是中医学术研究和临床应用的基础,在文献学习粤临床实践的基础上对老年肺炎的中医病机和治法进行理论探讨。
本研究为多中心随机双盲安慰剂对照试验。在5个分中心开展,将308例老年肺炎患者随机分为治疗组和对照组,两组各154例。治疗组采用西医基础抗感染治疗加扶正解毒化瘀颗粒治疗,对照组采用西医基础抗感染治疗加安慰剂治疗。
本研究疗程为1月,死亡和治愈(或好转)出院为终点事件,用药时间不超过4周。分别于治疗后第7天评测症状积分、胸片、血常规、血气分析、体温；第14天评测症状积分、血常规、痰涂片、细菌培养、咽拭子找支原体、血气分析、体温；第21天评测症状积分、胸片、血常规、血气分析、体温；第28天评测症状积分、胸片、血常规、痰涂片、细菌培养、咽拭子找支原体、血气分析、生命体征、尿便常规、肝肾功、心电图。死亡事件粤不良事件随时记录。
本论文主要统计分析基线资料；肺炎30天病死率；治疗后1周、2周的治愈率、症状积分、胸片吸收程度、血常规、血气分析及体温的变化情况。安全性评价采用报告表记录患者不良事件,并对治疗前后尿、大便常规,肝肾功能,心电图进行评价。
结果
通过文献学习、前期工作及临床实践总结,我们认为风温毒邪是老年性肺炎主要致病因素；热毒炽盛、痰瘀互结、正气亏虚是其核心病机。针对核心病机,治以扶正解毒化瘀法,中西医结合治疗可以提高疗效,具有降低病死率的趋势。临床试验共入组303例受试者。脱落17例,剔除2例,最后共有284例纳入统计分析。临床试验结果表明：
1治疗组发生死亡20例(13.89%),与对照组死亡16例(11.43%)比较,无统计学意义(p>0.05),这与样本量较少可能有关。但治疗组总病死率低于文献报道的30%-50%这一平均病死率,仍具有降低病死率的临床趋势,进一步扩大样本量可能出现统计学差异。
2两组第1周治愈率四分类等级分析,无统计学意义,但治疗组的趋势仍较对照组明显治疗组第2周有效率明显优于对照组,经X2检验,两组间有显著性差异(p=0.042)。结果表明,西医抗感染基础上配合中医扶正解毒化瘀法治疗老年肺炎,在一定程度上可以提高其临床疗效。
3治疗组在治疗后第1周、第2周能够明显改善咯痰症状积分,与对照组比较有统计学意义(p>0.05)；其它症状(咳嗽、发热、胸闷痛、气短懒言、喘息、口干舌燥、大便干结等)治疗前后有明显差异,但组间比较则无显著差异(P>0.05)。扶正解毒化瘀法能够在第1周改善咳痰症状；在第2周能够明显改善喘息、气短懒言等症状；但咳嗽、胸闷痛、倦怠乏力、口干舌燥、大便干结等症状治疗后的起效时间不确定。
4两组治疗后第1周、第2周外周血白细胞总数与中性粒细胞百分比均逐渐下降,治疗组下降趋势较对照组明显,但治疗组与对照组之间比较无显著差异(P>0.05)。扶正解毒化瘀法降低白细胞和中性粒细胞方面可能有一定优势,但是未发现统计学差异。
5随着治疗时间延长,两组血氧分压逐渐上升,二氧化碳分压逐渐下降；治疗组在治疗后第1周二氧化碳分压下降较对照组差异有统计学意义(P=0.039)；但两组间血氧分压升高比较则无显著差异(P>0.05)。
6本组资料中共有57例患者入组前有发热,对其服药后4h体温进行K-S检验,则4组数据都服从正态分布(P>0.05)。对两组间4个时间点作组间差异的t检验,则每个时间点上均无显著差异(P>0.05)。但从体温变化曲线来看,治疗组体温下降幅度略大于对照组,可以看出扶正解毒化瘀法具有即时退热的趋势。
7本组老年肺炎患者影像学资料具有以下特点：①病变部位多在下肺野；②病灶形态多数表现为肺纹理增重、模糊、紊乱,网格状阴影,斑点状或斑片状阴影,一般病变范围比较广泛；③支气管肺炎者居多；④容易伴发胸腔积液、肺气肿、肺不张等。两组治疗后胸片显示均存在一定程度的吸收或进展,但治疗后两组间比较并无显著性差异(P>0.05)。老年肺炎患者的炎症消散粤吸收一般需要2～3月时间,本研究资料集中在10～14天,故没能明确反映出两组间的差异。
8扶正解毒化瘀法安全性较好,治疗组144例患者中2例发生不良反应,发生率为1.39%；对照组140例患者中有3发生不良反应,发生率为2.14%；组间比较差别无统计学意义(P>0.05)。两组均未发生导致病例脱落的不良事件和严重不良事件。
结论
1老年肺炎的核心病机是热毒炽盛、痰瘀互结、正气亏虚,扶正解毒化瘀法是治疗老年肺炎的有效治法;
2扶正解毒化瘀法可以在第2周明显提高老年肺炎的治愈率；能够改善咳痰等单项症状积分,对咳痰、气短懒言、喘息等起效时间较早,显示该治法可以有效改善老年肺炎主要临床症状
3扶正解毒化瘀法能够改善老年肺炎的部分实验室指标,对降低外周血白细胞总数、中性粒细胞百分比等,具有一定的趋势；能够提高动脉血氧分压、降低二氧化碳分压,对于改善通气功能具有一定作用；
4扶正解毒化瘀法治疗老年肺炎,是通过干预老年肺炎病变过程中的“热、毒、痰、瘀、虚”等病理变化起作用；
5针对核心病机,确定扶正解毒化瘀法治疗老年肺炎,可以提高老年肺炎的治疗效果,在一定程度上反映出了老年肺炎发生、发展的内在规律；
6扶正解毒化瘀法治疗老年肺炎,在降低病死率方面有一定趋势,但与对照组比较无显著差异,可能粤样本量小有关,有待扩大样本量进一步研究；
7扶正解毒化瘀法治疗老年肺炎安全性较好,可以推广应用。
Objective
Senile Pneumonia is the most common lung infection in old population, notorious with its serious condition and bad prognosis. Morbidity and mortality of Senile Pneumonia are significantly higher than that of pneumonia in young people. Age, underlying disease, hospitalization caused by CAP and malnutrition are major risk factors of Senile Pneumonia. Bacterial infection is the most important pathogens of Senile Pneumonia.Endotoxin produced by Gram-negative bacteria can cause severe inflamm-ation cascade which promote the occurrence of SIRS, even the development of MODS, leading to death of patients. This pathological process is accordant with that of lung heat disease with wind-warm syndrome. "exuberance of heat-toxicity、intermingled phlegm and blood stasis、deficiency of vital qi "is the core pathogenesis of senile pneumonia. Wind-warm and toxicity pathogen are the main pathogenic factor. Heat and toxicity pathogens are always present in the whole course of the disease. The entanglement of exuberance of heat-toxicity、intermingled phlegm and blood stasis、over consumption of qi and fluid is the key factor leading to the extremely dangerous progress of lung heat disease with wind-warm syndrome. In order to reduce the mortality of senile pneumonia, we grasp the core of the pathogenesis of senile pneumonia, follow the principle of "strengthening vital qi to eliminate pathogenic factor", and establish the treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis". The purpose of our research is:①discuss the core of the pathogenesis of senile pneumonia and the treatment method of "strengthening vital qi,removing blood stasis";②evaluate the efficacy and safety of treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" in the intervention in elderly pneumonia mortality;③analyse causes, clinical features and distribution of syndromes, so as to provide clinical evidence for settlement of technical specifications of treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis".
Methods
The main object of the study are hospitalized pneumonia patients who are more than 65 years old. Senile Pneumonia is attributed to "lung heat disease with wind-warm syndrome"in Chinese medicine. Literatures of Chinese medicine are carrier of Chinese medicine theory and clinical experience and the basis for research and clinical application. Through learning literatures and clinical practice, we study the pathogenesis and treatment method of senile pneumonia in the theoretical layer.
Clinical research is conducted in five centers and the patients are divided into treatment group and control group according to the principles of randomization, with 154 cases of subjects in each group. The treatment group is interfered with anti-infection treatment and FuZhengJieDuHuaYu particle treatment, while the control group is interfered with anti-infection treatment and placebo.
The treatment lasts for one month, death and discharge after cure (or improvement) are the end of the treatment and the time for medication is no longer than 4 weeks.7 days after treatment, symptom score evaluation、chest radiograph、blood routine、blood gas analysis and body temperature are obtained; 14 days after treatment, symptom score evaluation、blood routine、sputum smear, bacterial culture、throat swab to find mycoplasma、blood gas analysis and body temperature, are obtained; 21 days after treatment, evaluation of symptom score, chest radiograph, blood routine, blood gas analysis and body temperature are obtained; 28 days after treatment, evaluation of symptom score, chest radiograph, blood routine, sputum smear, bacterial culture, throat swab to find mycoplasma, blood gas analysis, vital signs, urine and stool routine, liver and kidney function, ECG are obtained. Deaths and adverse events are recorded whenever they occur.
This study foucses on statistical analysis of baseline data; 30-day mortality of pneumonia; the cure rate, symptom score, chest X-ray absorption, blood routine, blood gas analysis and temperature changes 1 week and 2 weeks after treatment respectively. Safety evaluation is conducted by record of adverse reactions in patients, and evaluation of blood, urine and stool routine, liver and kidney function, ECG before and after treatment.
Results
Through literature study, preliminary work and summary of clinical practice, we believe that wind-warm and toxicity pathogen are the major risk factor of senile pneumonia; exuberance of heat-toxicity、intermingled phlegm and blood stasis、deficiency of vital qi are the core pathogenesis. Interfered with "strengthening vital qi,clearing toxicity,removing blood stasis" treatment,which is aimed at the core pathogenesis, therapy combined with westen and Chinese medicine can improve the efficacy of treatment with lower mortality.303 cases of clinical trial subjects were enrolled in this research,17 cases of which are lost and 2 cases are excluded and finally 284 cases are statistically analysed. Clinical trial results show that:
1 20 death cases in the treatment group (13.89%),16 death cases in the control group (11.43%) with no statistically significant difference (p>0.05), which may be related to small sample size. But overall mortality rate of the treatment group is lower than 30% to 50%, which is the average mortality rate reported by literature.If the sample size is enlarged, there may be statistical significance between the two groups.
2 Four classification level analysis of cure rate lweek after treatment shows no significant statistical difference between the two groups; chi-square test shows efficacy of treatment group is higher than that of control group with significant difference (p=0.042). The results show that anti-infection treatment combined with traditional Chinese medicine, to some certain extent, can improve clinical efficacy in the treatment of senile pneumonia.
3 Cough symptom score in treatment group can be obviously improved 1 week and 2 weeks after treatment with statistical significance compared with that of control group (p <0.05); other symptoms (cough, fever, chest pain, shortness of breath, disinclination to talk, breathe, dry mouth, dry stool, etc.) are significantly different before and after treatment, but between the two groups had no significant difference (p>0.05). The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" can relieve sputum in the first week after treatment; Symptoms such as breathing, shortness of breath and disinclination to talk can be significantly improved 2 weeks after treatment; but the time when cough, chest pain, malaise, fatigue, dry mouth, dry stools and other symptoms are effectively improved after treatment is uncertain.
4 WBC and neutrophil percentage have decreased in both groups with no significant difference (P>0.05).There may be some advantages for the treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" to reduce white blood cells and neutrophils, but there is no significant difference between the two groups.
5 As treatment time passes, blood oxygen gradually increases and carbon dioxide partial pressure decreases in both groups; partial pressure of carbon dioxide of treatment group compared with the control group decreased significantly 1 week after treatment (P=0.039); but there was no significant difference of the elevated blood oxygen pressure compared between the groups (P>0.05).
6 57 patients were with fever before they are enrolled, K-S test of their body tempera-ture 4 hours after taking the medicine shows the four sets of data are normally distributed (P> 0.05). Of the four time points between the two groups for differences between groups t-test, each time point were not significantly different (P>0.05). However, changes in body temperature curve show body temperature decrease in treatment group is slightly greater than that in the control group, which indicates real-time effect of decreasing body temperature with the use of the treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis".
7 Imaging data of this group of senile pneumonia has the following characteristics:①lesions are most common in lower lung field;②lesions manifest with blurred, disorder, grid-like shadow, the shadow of spots or patchy, usually the area of lesion is extensive;③bronchial pneumonia is the most common lesion;④usually associated with pleural effusion, emphysema, atelectasis, etc. Chest X-ray shows a degree of absorption and progress of the lesion, but there was no significant difference between the two groups after treatment (P> 0.05). Dissipation and absorption of inflammation in senile pneumonia usually takes 2 to 3 months and this research focuses on 10 to 14 days, thus this study did not clearly reflect the difference between the two groups.
8 The safety of the treatment method of "strengthening vital qi,clearing toxicity, removing blood stasis" is certain, there are only two cases of adverse reactions in 144 cases of treatment group, with an adverse reaction rate of 1.39%; there are three cases of adverse reactions in 140 cases of control group, with an occurance rate of 2.14%; there is no statistically significant difference between the two groups(P>0.05). There are no adverse events or serious adverse events leading to loss of subjects in both groups.
Conclusion
1 Exuberance of heat-toxicity、intermingled phlegm and blood stasis、deficiency of vital qi is the core of the pathogenesis of senile pneumonia and the treatment method of "strengthen-ing vital qi,clearing toxicity,removing blood stasis" is an effective treatment in senile pneumo-ma;
2 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" can significantly improve the cure rate of pneumonia two weeks after treatment; improve sputum and other individual symptom score; and has effect in the early stage to relieve cough, shortness of breath, disinclination to talk and breathing, indicating that the treatment method can effectively improve part of clinical symptoms in senile pneumonia;
3 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" can improve part of the laboratory parameters in senile pneumonia, such as WBC, neutrophils and other inflammatory markers; increase blood oxygen partial pressure, reduce carbon dioxide partial pressure,and improve ventilation to certain extent;
4 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" probably cures senile pneumonia by interfering with key factors in its pathological process, such as heat、toxicity、phlegm、blood stasis, deficiency";
5 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" aimed at the core pathogenesis can improve the treatment effectiveness of pneumonia in the elderly, which to a certain extent, reveals the inherent regularity of pneumonia in the elderly;
6 The fact that there is no significant statistical difference of mortality decrease between two groups may be related to the small sample size, thus sample size needs to be expanded in further study.
7 The treatment method of "strengthening vital qi,clearing toxicity,removing blood stasis" has relatively higher safety in the treatment of senile pneumonia and can be applied extensively.
引文
[1]王吉耀,廖二元,胡品津等.内科学.[M].北京：人民卫生出版社,2005：69.
[2]钟南山,府军,朱元饪等.现代呼吸肺详展.[M]北京:中国医药科技出版社,1994:166-168.
[3]Marston B I,Plouffe J F,File TMJR,et al.Incidence of community-acquired pneumonia requiring hospitalization:results of a population-based active surveillance study in Ohio.Arch Intern Med,1997,157(15):1709-1718.
[4]蹇在金,廖纪南.老年人肺炎的病因导临床.中华老年医学杂志,2004,23(10)：758-761.
[5]全国老龄工作委员会《2006：中国人口老龄化发展趋势预测研究报告》
[6]郑文峰.对中国人口老龄化的再认识.合作经济与科技,2005(4)：14.
[7]马红鸽.中国养老保险现状与对策研究.金融粤保险,2007(2)：36.
[8]Fein AM. Pneumonia in the dlderly:ocerciew of diaiagnostic and therapeutic approaches[J]. Ckub Infect Dis,1999,28:726-729.
[9]Marston BJ, Plouffe JF, File TM Jr,et al.Incidence of community-acquired pneumonia requiring hospitalization:results of a population-based active surveillance study in Ohio. The community-based pneumonia incidence study group. Arch Intern Med,1997, 157:1709-1718.
[10]Jackson ML,Neuzil KM,Thompson WW,et al.The burden of community-acquired pneumonia in seniors:results of a population-based study.Clin Infect Dis,2004,39 (11): 1642-1650.
[11]Ochoa Gondar O,Vila Creoles A,de Diego C,et al.The burden of community-acquired pneumonia in the elderly:the Spanish EVAN-65 stlldy.BMC Public Health,2008,8:222.
[12]Kothe H,Bauer T,Marre R,et al.Outcome of community-acquired pneumonia:influence of age.Residence status and antimicrobial treatment.Eur Respir J,2008,32(1):139-146.
[13]Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia:use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med,2002,166(5):717-23.
[14]Ramirez J A. Community-acquired pneumonia in adults[J].Prim Care,2003,30:155-171.
[15]DonaldWA,MatthewTK.Community-Acquired Pneumonia in Casualty:Etiology,Clinical Features,Diagnosis,and Management[J].Curr Opin Pulm Med,2004,10:166-170.
[16]Talwar A,Lee H,Fein A.Community-acquired pneumonia:what is relevant and what is not? [J].Curr Opin Pulm Med,2007,13 (3):177-185.
[17]Kaplan V, Clermont G, Griffin MF,et al. Pneumonia:still the old man's friend? Arch Intern Med.2003,163(3):317-23.
[18]胡必杰,何礼贤,殷少军,等.上海市下呼吸道医院感染的回顾性队列研究.中国抗感染化疗杂志,2002,(2)：74-77.
[19]何礼贤.医院获得性肺炎的诊断导治疗.见：戴瑞鸿,林果为,林唐金,等,主编.内科学新理论与新技术.第2版.上海科学技术教育出版社.2002,144-160.
[20]中华医学会呼吸病学分会.医院获得性肺炎诊断和治疗指南(草案).[J].中华结核和呼吸杂志,1999,22(4)：201.
[21]Marrie TJ.Community-acquired-pneumonia in the elderly.Clin Infect is.2000,31:1066-1078.
[22]Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med,1997,157:1453-1459.
[23]Riquelme R, Torres A, Ebiary M, et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med,1997,156:1908-1914.
[24]王秀香,杨敬平,乌日娜.老年人社区获得性肺炎的临床特征.临床肺科杂志,2008,13(4)：473.
[25]RiqueIme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med,1996, 154:1450-1455.
[26]Riquelme R, Torres A, Ebiary M, et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med,1997,156:1908-1914.
[27]Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest,2006,130:11-15.
[28]赵慧杰.血清C反应蛋白测定在肺部感染中的应用.中国误诊学杂志.2008,8：26.
[29]杭建明,丁明,李坚.社区获得性肺炎患者C反应蛋白的研究.江苏大学学报(医学版).2002,12(1)：16.
[30]李丽华,李春盛.C反应蛋白与全身炎症反应综合征和多脏器功能障碍综合征的关系.[J].中华急诊医学杂志,2003,12：48-49.
[31]Granton JT,Grossman RF. Community-acquired pneumonia in the elderly patient:clinical features, epidemiology, and treatment. Clin Chest Med,1993,14:537-553.
[32]Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med,1997,157:1453-1459.
[33]蒋丽娟,蔡冬梅,王涤非,等.老年社区获得性肺炎病原体分布和耐药性.中国老年学杂志,2005,25：717-718.
[34]唐柚青,郭振辉,邓青南,等.老年重症社区获得性肺炎与医院获得性肺炎的病原学特.实用医学杂志.2009,25(1)：136-137.
[35]张杏怡.社区获得性肺炎的抗菌药物治疗.[J].中国呼吸导危重监护杂志,2005；4(4)：258-260.
[36]Granton JT,Grossman RF. Community-acquired pneumonia in the elderly patient:clinical features, epidemiology, and treatment. Clin Chest Med,1993,14:537-553.
[37]中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南.中华结核和呼吸杂志,2006,29：651-655.
[38]American Thoracic Society,Infentious Diseases Society of America.Guidelines for the management of adults with hospital acquired, ventilator associated, and healthcare associated pneumonia.[J].Am J Respir Crit Care Med,2005,171(4):388-416.
[39]Torres A. The new American Thoracic Society/Infectious Disease Society of North America guidelines for the managment of hospital-acquired, Ventilator-associated and heahhcare-associated pneumonia a current view and new complementary information. [J]. Curt Opin Crit Care,2006,12(5):444-445.
[40]李家泰,李耘,王进.中国医院和社区获得性感染革兰阴性杆菌耐药监测研究.[J].中华医学杂志,2003,83(5)：365.
[41]孙铁英,蒲德.老年肺炎的特点和危害.[J].中华老年多器官疾病杂志,2005,4(1)：76.
[42]徐轶,何礼贤.老年患者医院获得性肺炎的危险因素.上海医学.2007,30(9)：663-664.
[43]钱淑文.调节吞咽和咳嗽反射预防老年人肺炎.[J].国外医学：老年分册,2002,23(5)：195.
[44]Moine P,Vercken JB,Chevret S,et al. Severe community-acquired Pneumonia:Etiology, epidemiology,andprognosis factors.Chest,1994,105:1487-1495.
[45]Lange P,Vestbo J,Nyboe J.Risk factors for death and hospitolization from pneumonia:A prospective study of a general population.Eur RespirJ,1995,8:1695-1698.
[46]Farr BM,Bartlett CL,Wadsworth J,et al.Risk factors for community-acquired pneumonia diagnosed upon hospital admission.Respir Med,2000,94:954-963.
[47]Farr BM, Woodhead MA, MacFarlane JT, et al.Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community.Respir Med,2000,94: ,422-427.
[48]Koivula Ⅰ, Sten M, Makela PH.Risk factors for pneumonia in the ederly.Am J Med,1994, 96:313-320.
[49]GrantonJT, GrossmanRF.Community-aequired Pneumonia in The elderly Patient:Clinical features,epidemiology,and treatment.Clin Chest Med 1993,14:537.
[50]Feldman C.Pneumonia in the elderly.Med Clin North AM,2001,85(6):1441-1459.
[51]Fedsion DS, Baldwin J A. Previous hospital care as a risk factor for pneumonia:implica-tions for immunization with pneumococcal vaccine[J].JAMA,1982,248:1989-1995.
[52]Kaplan V, Clermont G, Griffin MF, et al. Pneumonia:still the old man's friend? Arch Intern Med.2003,163(3):317-23.
[53]许能锋,李阳,陈娟娟,等.医院感染危险因素病例对照研究.[J].中国感染控制杂志,2005,4(2)：127-130.
[54]Husni RN, Goldstein LS, Arroliga AC,et al. Risk factors for an outbreak of multi -drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. [J]. Chest,1999, 115 (5):1378-1382
[55]施毅,宋勇等.现代肺部感染学.北京：人民军医出版社,1996：517-519.
[56]徐轶,何礼贤.老年患者医院获得性肺炎的危险因素.上海医学.2007,30(9)：663-664.
[57]Niederman MS,McCombs JS,Unger AN,et al.The cost of treating community-acquired pneumonia.Clin Ther.1998,20(4):820-37.
[58]Kronenberg R,Drage G. Attenuation of the ventilatory and Heart rate responses to hypoxia and hypereapnia with aging In normal man.J Clin Invest 1973;52:1812-19.
[59]Miller C,Kelsoe G.Ig VH hypermutation is absent in the germinal centers of aged mice. Jimmunol 1995:155:3377-84.
[60]Gyetko MR,Toews GB.Imunology of the aging lung.Clin Chest Med 1993;14:379-91.
[61]姚魁武,李建生,马利军,等.老年肺炎营养状况探讨.[J].北京中医药大学学报,2003,26(4)：72-74.
[62]侯恕.呼吸病的营养支持.[Jl.中华结核和呼吸杂志,1996,19(3):133-135.
[63]耿德章.中国老年医学.[M].北京：人民卫生出版社,2002,390-391.
[64]施毅,宋勇.现代肺部感染学.[M].北京：人民军医出版社,1996,507.
[65]Meyer KC, Ershler W, Rosenthal NS, et al.Immune dysregulation in the aging human lung[J].Am J Respir Crit Care Med,1996,153(3):1072-1079.
[66]高越,王弋,何建如,等.重症肺炎患者T淋巴细胞亚群的研究.[J].宁夏医学杂志,2002,24(6)：331-332.
[67]杨明,张晓春,方芳.老年肺心病急性期患者免疫功能的分析.[J].心血管康复医学杂志,2002,11(4)：330-331.
[68]任少华.老年肺的免疫功能失调.国外医学免疫学分册,1997,20(3)：166.
[69]林文棠,朱平.实用临床免疫学.西安：第四军医大学出版社,2003,205.
[70]吴开松,徐献群,徐(?)勇.老年肺部感染患者T细胞亚群、NK细胞活性及可溶性白介素-2受体变化及临床意义.中华医院感染学杂志,2002,12(5)：347-348.
[71]侯立朝,熊利泽,尚磊,等.胸腺肽α1对重症肺部感染患者T淋巴细胞亚群比例的影响[J].中华麻醉学杂志,2006,26(11)：1005-1007.
[72]梁颖,习昕,刘双.成人重症社区获得性肺炎的诊治进展.[J].中国全科医学.2008,11(6A)：1005-1007.
[73]Marik PE. Aspiration Pneumonitis and aspiration Pneumonia.N Engl J Med 2001:344: 665-71.
[74]Marik PE. Aspiration Pneumonitis and aspiration Pneumonia.N Engl J Med 2001:344: 665-71.
[75]徐轶,何礼贤.老年患者医院获得性肺炎的危险因素.上海医学.2007,30(9)：663-664.
[76]Sekizwaa K, SasakiH.High incidence of silent aspiration In elderly Patients with community aequired Pneumonia.Am J Respir Crit Care Med.1994; 150:251-53.
[77]Young PJ,Ridley SA.Ventilator Associated Pneumonia.Diagnosis Pathogenesis and Prevention[J].Anaesthesia,1999,54:1183-1197.
[78]Mathews P J,Mathews L M.Reducing the Risks of Ventilator Associated Infections. [J]. Dimens Crit Care Nurs,2000,19:17-21.
[79]Kollef M H.Epidemiology and Risk Factors for Nosocomial Pneumonia[J].Clin Chest Med,1999,20:653-670.
[80]PalmerLB,Albulak K,Fields S,etal.Oral clearance and PathogenieoroPharyngeal coloniza-tion in the elderly.Am J Respir Crit Care Med 2001:164:464-68.
[81]陆亿华,余姚凤.某医院获得性肺炎调查分析.[J].浙江预防医学.2003,15(2)：32-33.
[82]Trautmann M,Lauterbacher F,Moricke A.Endotxin-freisetzung durch piperacillin-tazobactam im vergleich mit ceftazidim.[J].Chemother J,2000,9:126
[83]叶任高,陆再英.内科学.[M].北京:人民卫生出版社,2004:150-151.
[84]黄志勇,邹小明,陈钢.胸部术后多器官功能不全综合症的临床危险因素探讨.[J].中国危重病急救杂志,2001,13(9)：553-554.
[85]王士雯,韩亚玲,钱小顺.1605例老年多器官功能衰竭的临床分析.[J].中华老年多器官疾病杂志,2002,1(1)：10.
[86]中华医学会呼吸学分会.社区获得性肺炎诊断和治疗指南.[J].中华结核和呼吸杂志,2006,29(10)：653-654.
[87]Mandell LA,Wunderink RG,Anzueto A,et a1.Infectious Diseases Society of American/ American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adult[J].Clin Infect Dis,2007,44(Suppl):S27-72.
[88]Niederman MS,Ahmed QA.Community-acquired pneumonia in elderly patients[J].Clin Geriatr Med,2003,19:101
[89]Fine MJ,Auble TE,Yealy DM,et al.A prediction rule to identify low -risk patients with community-acquired pneumonia.N Engl J Med,1997,336:243-250.
[90]Fine MJ.Risk stratification for patients with community-acquired pneumonia.Int J Clin Pract Suppl,2000,115:14-17.
[91]胡迅.老年社区获得性肺炎病原菌及药敏试验结果分析.实用预防医学,2001,8(6)：437
[92]周新.美国2005年院内获得性肺炎诊治指南要点与解读.中国实用内科杂志,2006,26(4)：295
[93]马壮.老年肺炎的病原学特点导治疗.解放军保健医学杂志,2005,7(2)：120.
[1]周仲瑛,周光,陈文恺.辨证施治肺炎40例的临床分析.新中医,1982,(3)：32.
[2]陈泽霖,宋祖敬.名医特色经验精华.[M]上海：上海中医学院出版社,1987,124.
[3]风温肺热病、中风病诊疗标准.山东中医学院学报,1986,10(4)：70-72.
[4]杨进.新编温病学.[M].北京：学苑出版社,2003.36-38.
[5]秦伯未.谦斋医学讲稿.[M].上海：上海科学技术出版社,2009：81.
[6]万友生.热病学.[M].重庆：重庆出版社,1989.
[7]陆渊雷.伤寒论今释.[M].北京：人民卫生出版社,1955：3.
[8]赵绍琴.肺炎证治.中医杂志,1985,(10)：6.
[9]黄星垣.中医内科急症治疗研究粤探讨.云南中医杂志,1981,(1)：22.
[10]殷允诚.陈宪海辨治老年人肺炎经验拾萃.湖北中医杂志,2004,26(7)：18.
[11]李建生.老年人社区获得性肺炎中医辨证治疗概要.中医学报.2010,5(3)：440.
[12]周耀端.泻白散加味治疗老年肺炎58例临床观察.湖南中医杂志,1996,(5)：14-15.
[13]童丽,李贻奎.化痰养阴法治疗老年人肺炎33例体会.青海医药杂志.2000,30(11)：64.
[14]潘钦松.老年肺炎辨治一得.江苏中医药,2003,24(7)：39.
[15]付国华.中药治疗老年性肺炎临床体会.陕西中医,2003,24(4)：381.
[16]万啟南,李游.中西医治疗老年人肺炎64例观察.实用中医药杂志,2006,22(2)：88.
[17]郭红.中西医结合治疗老年人肺感染88例疗效观察.天津中医,1998,(4)：153-154.
[18]洪旭初,陈沁.中西药合用治疗老年肺炎40例.实用中医药杂志,1998,(2)：32-33.
[19]高玉龙,陈和平.胸腺肽加复方丹参注射液治疗老年肺炎101例体会.实用中西医结合杂志.1996,(1)：61.
[20]苗林,王美村,马丽君,等.理气冲剂对老年人慢阻肺感染的疗效观察.中医药学报,1994,(2)：43-44.
[21]郭谦亨.温病述评.[M].西安：陕西科学技术出版社,1987：72.
[22]周仲英,等.辨证施治肺炎40例的临床分析.新中医.1982,(3)：32.
[23]王成祥.辨证治疗老年风温肺热55例.中国中医急症.1992,1(1)：33.
[24]杨素敏,欧阳东.老年肺炎的临床特点导中西医结合治疗.中国自然医学杂志,2000,2(2)：75-78.
[25]风温肺热病、中风病诊疗标准.山东中医学院学报,1986,10(4)：70-72.
[26]徐振华.温胆汤治疗金黄色葡萄球菌肺炎100例.新中医.1994,(3)：50.
[27]张瑞利.加减宣白承气汤治疗急性肺部感染150例.浙江中医杂志.1997,(6)：252.
[28]李建生.老年人肺炎的特点与治疗.河南中医,2000,20(6)：1-4.
[29]周国雄.中医老年病治疗学.广东：广东科技出版社,1993,7(1)：91-92.
[30]李海宁.中西医结合治疗社区获得性肺炎39例疗效观察.山西中医.2006,22(1)：25.
[31]张清,郑艳,郑承铎.加味麻杏石甘汤治疗老年性肺炎48例.[J].现代医药卫生.2005,21(13)：1711-1712.
[32]姚亮,宋文宝.黄芪注射液佐治老年性肺炎疗效观察.[J].河南中医.2004,24(11)：33-34.
[1]毛泽东.毛泽东选集.[M].北京.人民出版社.1991：302.
[2]印会河,张伯讷.中医基础理论.[M].上海.上海科学技术出版社.1984：102.
[3]郭谦亨.温病述评.[M].西安.陕西科学技术出版社,1987：50.
[4]周耀端,黄益兰.泻白散加味治疗老年肺炎58例临床观察.湖南中医杂,1996,(5)：14-15.
[5]赵新乡.老年肺部感染的辨证论治.山西中医,2003,19(2)：63.
[6]纪有福,魏钰.中医治疗老年性肺炎临床体会.光明中医,1998,(3)：16-17.
[7]殷允诚.陈宪海辨治老年人肺炎经验拾萃.湖北中医杂志,2004,26(7)：18-19.
[8]唐险峰,张永红,蔡勇.老年人社区获得性肺炎的临床特点.中华现代临床医学杂志.2008,6(2)：138.
[9]黄星垣.中医内科急症治疗研究与探讨.云南中医杂志,1981,(1)：22.
[10]孟澍江.“毒”在温病发病中的意义.中医杂志,1991,(1)：6.
[11]徐应抒.温病卫气营血症候103例微循环和血液流变学研究.中医杂志,1986,(8)：39.
[12]姜春华.扭转截断重祛邢先证而治勿因循.中国社区医师,2003,18(11)；21-22.
[13]贝润浦.论中医截断扭转之法(上).浙江中医杂志.2009,44(7)：469-470.
[14]李鸣真,叶望云,陆付耳等.中医“清热解毒法”实质的研究.[J].浙江中西医结合 志,2000,10(8)：449-450.
[15]王今达,崔乃杰,宗育彬,等.内毒素性多系统脏器衰竭发病机理的新概念及防治措施新理论实验研究.[J].危重病急救医学,1989,1(1)：17.
[16]王今达,高天元,崔乃杰,等.祖国医学“肺粤大肠相表里”学说的临床意义及其本质的探讨--临床病例分析导实验研究.[J].中西医结合杂志,1982,2(2)：27.
[17]王今达,雪琳.细菌、内毒素、炎性介质并治-治疗重症脓毒病的新对策.[J].中国危重病急救医学.1998,10(6)：323-325.
[18]王华东.清热解毒理气活血方药防治LPS性多器官功能衰竭的机制研究.[D].北京：北京中医药大学,2004.
[19]王成祥,高桂新,魏守超,徐红日.益气清瘟解毒合剂对流感病毒FM1感染小鼠肺中IFN-γ,TNF-a,IL-10及IL-6蛋白动态表达的影响.中国中药杂志,2005,30(7)：541-544.
[20]赵东英.抗流感合剂治疗流行性感冒的临床研究.浙江中医杂志,2006,41(6)：326-327.
[21]张艺平.中药抗内毒素研究新进展.中国中西医结合急救杂志,2001,8(2)：122-124.
[22]刘云海.青蒿素等中药化学成分抗内毒素研究现状.医药导报,2001,20(8)：525-526.
[23]李鸣真.清热解毒法的作用特点和优势.第二次世界中西医结合大会论文,503.
[24]姜春华.扭转截断重祛邪 先证而治勿因循.中国社区医师.2003,18(11)：21.
[25]张庆立,朱保权,王爱华.D-二聚体测定在婴儿重症肺炎高凝状态时的应用.[J].临床儿科杂志.2004,22(5)：302-303.
[26]Niederman MS, Brito V. Pneumon ia in the older patient.[J].Clin Chest Med,2007,28(4): 751-771.
[27]Guneysel O, Pirmit S, Karakurt S. Plasma d-dimer levels increase with the severity of comm un it ac uire d pneumonia.[J].Tuberk Toraks,2004,52(4):341-347.
[28]闫梅,张成等.老年肺炎患者血清D-二聚体水平变化.中国全科医学.2009,2：240-241.
[29]Fabian TC,Minard G.Sepsis.[A].Mattox KL.Complications of trauma.[M].New York: Churchill Livingstone.1994,61-80.
[30]胡森.MODS动物模型研究进展.中国危重病急救医学.1999,11(8)：506.
[31]赵炳南.益气养阴法治疗败血症探讨.[J].辽宁中医杂志,1997,24(12)：341.
[2]钟南山,府军,朱元饪等.现代呼吸肺详展.[M]北京:中国医药科技出版社,1994:166-168.
[3]Marston B I,Plouffe J F,File TMJR,et al.Incidence of community-acquired pneumonia requiring hospitalization:results of a population-based active surveillance study in Ohio.Arch Intern Med,1997,157(15):1709-1718.
[4]蹇在金,廖纪南.老年人肺炎的病因导临床.中华老年医学杂志,2004,23(10)：758-761.
[5]全国老龄工作委员会《2006：中国人口老龄化发展趋势预测研究报告》
[6]郑文峰.对中国人口老龄化的再认识.合作经济与科技,2005(4)：14.
[7]马红鸽.中国养老保险现状与对策研究.金融粤保险,2007(2)：36.
[8]Fein AM. Pneumonia in the dlderly:ocerciew of diaiagnostic and therapeutic approaches[J]. Ckub Infect Dis,1999,28:726-729.
[9]Marston BJ, Plouffe JF, File TM Jr,et al.Incidence of community-acquired pneumonia requiring hospitalization:results of a population-based active surveillance study in Ohio. The community-based pneumonia incidence study group. Arch Intern Med,1997, 157:1709-1718.
[10]Jackson ML,Neuzil KM,Thompson WW,et al.The burden of community-acquired pneumonia in seniors:results of a population-based study.Clin Infect Dis,2004,39 (11): 1642-1650.
[11]Ochoa Gondar O,Vila Creoles A,de Diego C,et al.The burden of community-acquired pneumonia in the elderly:the Spanish EVAN-65 stlldy.BMC Public Health,2008,8:222.
[12]Kothe H,Bauer T,Marre R,et al.Outcome of community-acquired pneumonia:influence of age.Residence status and antimicrobial treatment.Eur Respir J,2008,32(1):139-146.
[13]Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia:use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med,2002,166(5):717-23.
[14]Ramirez J A. Community-acquired pneumonia in adults[J].Prim Care,2003,30:155-171.
[15]DonaldWA,MatthewTK.Community-Acquired Pneumonia in Casualty:Etiology,Clinical Features,Diagnosis,and Management[J].Curr Opin Pulm Med,2004,10:166-170.
[16]Talwar A,Lee H,Fein A.Community-acquired pneumonia:what is relevant and what is not? [J].Curr Opin Pulm Med,2007,13 (3):177-185.
[17]Kaplan V, Clermont G, Griffin MF,et al. Pneumonia:still the old man's friend? Arch Intern Med.2003,163(3):317-23.
[18]胡必杰,何礼贤,殷少军,等.上海市下呼吸道医院感染的回顾性队列研究.中国抗感染化疗杂志,2002,(2)：74-77.
[19]何礼贤.医院获得性肺炎的诊断导治疗.见：戴瑞鸿,林果为,林唐金,等,主编.内科学新理论与新技术.第2版.上海科学技术教育出版社.2002,144-160.
[20]中华医学会呼吸病学分会.医院获得性肺炎诊断和治疗指南(草案).[J].中华结核和呼吸杂志,1999,22(4)：201.
[21]Marrie TJ.Community-acquired-pneumonia in the elderly.Clin Infect is.2000,31:1066-1078.
[22]Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med,1997,157:1453-1459.
[23]Riquelme R, Torres A, Ebiary M, et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med,1997,156:1908-1914.
[24]王秀香,杨敬平,乌日娜.老年人社区获得性肺炎的临床特征.临床肺科杂志,2008,13(4)：473.
[25]RiqueIme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med,1996, 154:1450-1455.
[26]Riquelme R, Torres A, Ebiary M, et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med,1997,156:1908-1914.
[27]Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest,2006,130:11-15.
[28]赵慧杰.血清C反应蛋白测定在肺部感染中的应用.中国误诊学杂志.2008,8：26.
[29]杭建明,丁明,李坚.社区获得性肺炎患者C反应蛋白的研究.江苏大学学报(医学版).2002,12(1)：16.
[30]李丽华,李春盛.C反应蛋白与全身炎症反应综合征和多脏器功能障碍综合征的关系.[J].中华急诊医学杂志,2003,12：48-49.
[31]Granton JT,Grossman RF. Community-acquired pneumonia in the elderly patient:clinical features, epidemiology, and treatment. Clin Chest Med,1993,14:537-553.
[32]Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med,1997,157:1453-1459.
[33]蒋丽娟,蔡冬梅,王涤非,等.老年社区获得性肺炎病原体分布和耐药性.中国老年学杂志,2005,25：717-718.
[34]唐柚青,郭振辉,邓青南,等.老年重症社区获得性肺炎与医院获得性肺炎的病原学特.实用医学杂志.2009,25(1)：136-137.
[35]张杏怡.社区获得性肺炎的抗菌药物治疗.[J].中国呼吸导危重监护杂志,2005；4(4)：258-260.
[36]Granton JT,Grossman RF. Community-acquired pneumonia in the elderly patient:clinical features, epidemiology, and treatment. Clin Chest Med,1993,14:537-553.
[37]中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南.中华结核和呼吸杂志,2006,29：651-655.
[38]American Thoracic Society,Infentious Diseases Society of America.Guidelines for the management of adults with hospital acquired, ventilator associated, and healthcare associated pneumonia.[J].Am J Respir Crit Care Med,2005,171(4):388-416.
[39]Torres A. The new American Thoracic Society/Infectious Disease Society of North America guidelines for the managment of hospital-acquired, Ventilator-associated and heahhcare-associated pneumonia a current view and new complementary information. [J]. Curt Opin Crit Care,2006,12(5):444-445.
[40]李家泰,李耘,王进.中国医院和社区获得性感染革兰阴性杆菌耐药监测研究.[J].中华医学杂志,2003,83(5)：365.
[41]孙铁英,蒲德.老年肺炎的特点和危害.[J].中华老年多器官疾病杂志,2005,4(1)：76.
[42]徐轶,何礼贤.老年患者医院获得性肺炎的危险因素.上海医学.2007,30(9)：663-664.
[43]钱淑文.调节吞咽和咳嗽反射预防老年人肺炎.[J].国外医学：老年分册,2002,23(5)：195.
[44]Moine P,Vercken JB,Chevret S,et al. Severe community-acquired Pneumonia:Etiology, epidemiology,andprognosis factors.Chest,1994,105:1487-1495.
[45]Lange P,Vestbo J,Nyboe J.Risk factors for death and hospitolization from pneumonia:A prospective study of a general population.Eur RespirJ,1995,8:1695-1698.
[46]Farr BM,Bartlett CL,Wadsworth J,et al.Risk factors for community-acquired pneumonia diagnosed upon hospital admission.Respir Med,2000,94:954-963.
[47]Farr BM, Woodhead MA, MacFarlane JT, et al.Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community.Respir Med,2000,94: ,422-427.
[48]Koivula Ⅰ, Sten M, Makela PH.Risk factors for pneumonia in the ederly.Am J Med,1994, 96:313-320.
[49]GrantonJT, GrossmanRF.Community-aequired Pneumonia in The elderly Patient:Clinical features,epidemiology,and treatment.Clin Chest Med 1993,14:537.
[50]Feldman C.Pneumonia in the elderly.Med Clin North AM,2001,85(6):1441-1459.
[51]Fedsion DS, Baldwin J A. Previous hospital care as a risk factor for pneumonia:implica-tions for immunization with pneumococcal vaccine[J].JAMA,1982,248:1989-1995.
[52]Kaplan V, Clermont G, Griffin MF, et al. Pneumonia:still the old man's friend? Arch Intern Med.2003,163(3):317-23.
[53]许能锋,李阳,陈娟娟,等.医院感染危险因素病例对照研究.[J].中国感染控制杂志,2005,4(2)：127-130.
[54]Husni RN, Goldstein LS, Arroliga AC,et al. Risk factors for an outbreak of multi -drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. [J]. Chest,1999, 115 (5):1378-1382
[55]施毅,宋勇等.现代肺部感染学.北京：人民军医出版社,1996：517-519.
[56]徐轶,何礼贤.老年患者医院获得性肺炎的危险因素.上海医学.2007,30(9)：663-664.
[57]Niederman MS,McCombs JS,Unger AN,et al.The cost of treating community-acquired pneumonia.Clin Ther.1998,20(4):820-37.
[58]Kronenberg R,Drage G. Attenuation of the ventilatory and Heart rate responses to hypoxia and hypereapnia with aging In normal man.J Clin Invest 1973;52:1812-19.
[59]Miller C,Kelsoe G.Ig VH hypermutation is absent in the germinal centers of aged mice. Jimmunol 1995:155:3377-84.
[60]Gyetko MR,Toews GB.Imunology of the aging lung.Clin Chest Med 1993;14:379-91.
[61]姚魁武,李建生,马利军,等.老年肺炎营养状况探讨.[J].北京中医药大学学报,2003,26(4)：72-74.
[62]侯恕.呼吸病的营养支持.[Jl.中华结核和呼吸杂志,1996,19(3):133-135.
[63]耿德章.中国老年医学.[M].北京：人民卫生出版社,2002,390-391.
[64]施毅,宋勇.现代肺部感染学.[M].北京：人民军医出版社,1996,507.
[65]Meyer KC, Ershler W, Rosenthal NS, et al.Immune dysregulation in the aging human lung[J].Am J Respir Crit Care Med,1996,153(3):1072-1079.
[66]高越,王弋,何建如,等.重症肺炎患者T淋巴细胞亚群的研究.[J].宁夏医学杂志,2002,24(6)：331-332.
[67]杨明,张晓春,方芳.老年肺心病急性期患者免疫功能的分析.[J].心血管康复医学杂志,2002,11(4)：330-331.
[68]任少华.老年肺的免疫功能失调.国外医学免疫学分册,1997,20(3)：166.
[69]林文棠,朱平.实用临床免疫学.西安：第四军医大学出版社,2003,205.
[70]吴开松,徐献群,徐(?)勇.老年肺部感染患者T细胞亚群、NK细胞活性及可溶性白介素-2受体变化及临床意义.中华医院感染学杂志,2002,12(5)：347-348.
[71]侯立朝,熊利泽,尚磊,等.胸腺肽α1对重症肺部感染患者T淋巴细胞亚群比例的影响[J].中华麻醉学杂志,2006,26(11)：1005-1007.
[72]梁颖,习昕,刘双.成人重症社区获得性肺炎的诊治进展.[J].中国全科医学.2008,11(6A)：1005-1007.
[73]Marik PE. Aspiration Pneumonitis and aspiration Pneumonia.N Engl J Med 2001:344: 665-71.
[74]Marik PE. Aspiration Pneumonitis and aspiration Pneumonia.N Engl J Med 2001:344: 665-71.
[75]徐轶,何礼贤.老年患者医院获得性肺炎的危险因素.上海医学.2007,30(9)：663-664.
[76]Sekizwaa K, SasakiH.High incidence of silent aspiration In elderly Patients with community aequired Pneumonia.Am J Respir Crit Care Med.1994; 150:251-53.
[77]Young PJ,Ridley SA.Ventilator Associated Pneumonia.Diagnosis Pathogenesis and Prevention[J].Anaesthesia,1999,54:1183-1197.
[78]Mathews P J,Mathews L M.Reducing the Risks of Ventilator Associated Infections. [J]. Dimens Crit Care Nurs,2000,19:17-21.
[79]Kollef M H.Epidemiology and Risk Factors for Nosocomial Pneumonia[J].Clin Chest Med,1999,20:653-670.
[80]PalmerLB,Albulak K,Fields S,etal.Oral clearance and PathogenieoroPharyngeal coloniza-tion in the elderly.Am J Respir Crit Care Med 2001:164:464-68.
[81]陆亿华,余姚凤.某医院获得性肺炎调查分析.[J].浙江预防医学.2003,15(2)：32-33.
[82]Trautmann M,Lauterbacher F,Moricke A.Endotxin-freisetzung durch piperacillin-tazobactam im vergleich mit ceftazidim.[J].Chemother J,2000,9:126
[83]叶任高,陆再英.内科学.[M].北京:人民卫生出版社,2004:150-151.
[84]黄志勇,邹小明,陈钢.胸部术后多器官功能不全综合症的临床危险因素探讨.[J].中国危重病急救杂志,2001,13(9)：553-554.
[85]王士雯,韩亚玲,钱小顺.1605例老年多器官功能衰竭的临床分析.[J].中华老年多器官疾病杂志,2002,1(1)：10.
[86]中华医学会呼吸学分会.社区获得性肺炎诊断和治疗指南.[J].中华结核和呼吸杂志,2006,29(10)：653-654.
[87]Mandell LA,Wunderink RG,Anzueto A,et a1.Infectious Diseases Society of American/ American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adult[J].Clin Infect Dis,2007,44(Suppl):S27-72.
[88]Niederman MS,Ahmed QA.Community-acquired pneumonia in elderly patients[J].Clin Geriatr Med,2003,19:101
[89]Fine MJ,Auble TE,Yealy DM,et al.A prediction rule to identify low -risk patients with community-acquired pneumonia.N Engl J Med,1997,336:243-250.
[90]Fine MJ.Risk stratification for patients with community-acquired pneumonia.Int J Clin Pract Suppl,2000,115:14-17.
[91]胡迅.老年社区获得性肺炎病原菌及药敏试验结果分析.实用预防医学,2001,8(6)：437
[92]周新.美国2005年院内获得性肺炎诊治指南要点与解读.中国实用内科杂志,2006,26(4)：295
[93]马壮.老年肺炎的病原学特点导治疗.解放军保健医学杂志,2005,7(2)：120.
[1]周仲瑛,周光,陈文恺.辨证施治肺炎40例的临床分析.新中医,1982,(3)：32.
[2]陈泽霖,宋祖敬.名医特色经验精华.[M]上海：上海中医学院出版社,1987,124.
[3]风温肺热病、中风病诊疗标准.山东中医学院学报,1986,10(4)：70-72.
[4]杨进.新编温病学.[M].北京：学苑出版社,2003.36-38.
[5]秦伯未.谦斋医学讲稿.[M].上海：上海科学技术出版社,2009：81.
[6]万友生.热病学.[M].重庆：重庆出版社,1989.
[7]陆渊雷.伤寒论今释.[M].北京：人民卫生出版社,1955：3.
[8]赵绍琴.肺炎证治.中医杂志,1985,(10)：6.
[9]黄星垣.中医内科急症治疗研究粤探讨.云南中医杂志,1981,(1)：22.
[10]殷允诚.陈宪海辨治老年人肺炎经验拾萃.湖北中医杂志,2004,26(7)：18.
[11]李建生.老年人社区获得性肺炎中医辨证治疗概要.中医学报.2010,5(3)：440.
[12]周耀端.泻白散加味治疗老年肺炎58例临床观察.湖南中医杂志,1996,(5)：14-15.
[13]童丽,李贻奎.化痰养阴法治疗老年人肺炎33例体会.青海医药杂志.2000,30(11)：64.
[14]潘钦松.老年肺炎辨治一得.江苏中医药,2003,24(7)：39.
[15]付国华.中药治疗老年性肺炎临床体会.陕西中医,2003,24(4)：381.
[16]万啟南,李游.中西医治疗老年人肺炎64例观察.实用中医药杂志,2006,22(2)：88.
[17]郭红.中西医结合治疗老年人肺感染88例疗效观察.天津中医,1998,(4)：153-154.
[18]洪旭初,陈沁.中西药合用治疗老年肺炎40例.实用中医药杂志,1998,(2)：32-33.
[19]高玉龙,陈和平.胸腺肽加复方丹参注射液治疗老年肺炎101例体会.实用中西医结合杂志.1996,(1)：61.
[20]苗林,王美村,马丽君,等.理气冲剂对老年人慢阻肺感染的疗效观察.中医药学报,1994,(2)：43-44.
[21]郭谦亨.温病述评.[M].西安：陕西科学技术出版社,1987：72.
[22]周仲英,等.辨证施治肺炎40例的临床分析.新中医.1982,(3)：32.
[23]王成祥.辨证治疗老年风温肺热55例.中国中医急症.1992,1(1)：33.
[24]杨素敏,欧阳东.老年肺炎的临床特点导中西医结合治疗.中国自然医学杂志,2000,2(2)：75-78.
[25]风温肺热病、中风病诊疗标准.山东中医学院学报,1986,10(4)：70-72.
[26]徐振华.温胆汤治疗金黄色葡萄球菌肺炎100例.新中医.1994,(3)：50.
[27]张瑞利.加减宣白承气汤治疗急性肺部感染150例.浙江中医杂志.1997,(6)：252.
[28]李建生.老年人肺炎的特点与治疗.河南中医,2000,20(6)：1-4.
[29]周国雄.中医老年病治疗学.广东：广东科技出版社,1993,7(1)：91-92.
[30]李海宁.中西医结合治疗社区获得性肺炎39例疗效观察.山西中医.2006,22(1)：25.
[31]张清,郑艳,郑承铎.加味麻杏石甘汤治疗老年性肺炎48例.[J].现代医药卫生.2005,21(13)：1711-1712.
[32]姚亮,宋文宝.黄芪注射液佐治老年性肺炎疗效观察.[J].河南中医.2004,24(11)：33-34.
[1]毛泽东.毛泽东选集.[M].北京.人民出版社.1991：302.
[2]印会河,张伯讷.中医基础理论.[M].上海.上海科学技术出版社.1984：102.
[3]郭谦亨.温病述评.[M].西安.陕西科学技术出版社,1987：50.
[4]周耀端,黄益兰.泻白散加味治疗老年肺炎58例临床观察.湖南中医杂,1996,(5)：14-15.
[5]赵新乡.老年肺部感染的辨证论治.山西中医,2003,19(2)：63.
[6]纪有福,魏钰.中医治疗老年性肺炎临床体会.光明中医,1998,(3)：16-17.
[7]殷允诚.陈宪海辨治老年人肺炎经验拾萃.湖北中医杂志,2004,26(7)：18-19.
[8]唐险峰,张永红,蔡勇.老年人社区获得性肺炎的临床特点.中华现代临床医学杂志.2008,6(2)：138.
[9]黄星垣.中医内科急症治疗研究与探讨.云南中医杂志,1981,(1)：22.
[10]孟澍江.“毒”在温病发病中的意义.中医杂志,1991,(1)：6.
[11]徐应抒.温病卫气营血症候103例微循环和血液流变学研究.中医杂志,1986,(8)：39.
[12]姜春华.扭转截断重祛邢先证而治勿因循.中国社区医师,2003,18(11)；21-22.
[13]贝润浦.论中医截断扭转之法(上).浙江中医杂志.2009,44(7)：469-470.
[14]李鸣真,叶望云,陆付耳等.中医“清热解毒法”实质的研究.[J].浙江中西医结合 志,2000,10(8)：449-450.
[15]王今达,崔乃杰,宗育彬,等.内毒素性多系统脏器衰竭发病机理的新概念及防治措施新理论实验研究.[J].危重病急救医学,1989,1(1)：17.
[16]王今达,高天元,崔乃杰,等.祖国医学“肺粤大肠相表里”学说的临床意义及其本质的探讨--临床病例分析导实验研究.[J].中西医结合杂志,1982,2(2)：27.
[17]王今达,雪琳.细菌、内毒素、炎性介质并治-治疗重症脓毒病的新对策.[J].中国危重病急救医学.1998,10(6)：323-325.
[18]王华东.清热解毒理气活血方药防治LPS性多器官功能衰竭的机制研究.[D].北京：北京中医药大学,2004.
[19]王成祥,高桂新,魏守超,徐红日.益气清瘟解毒合剂对流感病毒FM1感染小鼠肺中IFN-γ,TNF-a,IL-10及IL-6蛋白动态表达的影响.中国中药杂志,2005,30(7)：541-544.
[20]赵东英.抗流感合剂治疗流行性感冒的临床研究.浙江中医杂志,2006,41(6)：326-327.
[21]张艺平.中药抗内毒素研究新进展.中国中西医结合急救杂志,2001,8(2)：122-124.
[22]刘云海.青蒿素等中药化学成分抗内毒素研究现状.医药导报,2001,20(8)：525-526.
[23]李鸣真.清热解毒法的作用特点和优势.第二次世界中西医结合大会论文,503.
[24]姜春华.扭转截断重祛邪 先证而治勿因循.中国社区医师.2003,18(11)：21.
[25]张庆立,朱保权,王爱华.D-二聚体测定在婴儿重症肺炎高凝状态时的应用.[J].临床儿科杂志.2004,22(5)：302-303.
[26]Niederman MS, Brito V. Pneumon ia in the older patient.[J].Clin Chest Med,2007,28(4): 751-771.
[27]Guneysel O, Pirmit S, Karakurt S. Plasma d-dimer levels increase with the severity of comm un it ac uire d pneumonia.[J].Tuberk Toraks,2004,52(4):341-347.
[28]闫梅,张成等.老年肺炎患者血清D-二聚体水平变化.中国全科医学.2009,2：240-241.
[29]Fabian TC,Minard G.Sepsis.[A].Mattox KL.Complications of trauma.[M].New York: Churchill Livingstone.1994,61-80.
[30]胡森.MODS动物模型研究进展.中国危重病急救医学.1999,11(8)：506.
[31]赵炳南.益气养阴法治疗败血症探讨.[J].辽宁中医杂志,1997,24(12)：341.